(1,3,5-三甲基-1H-吡唑-4-基)硼酸 | 847818-62-6

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (1,3,5-三甲基-1H-吡唑-4-基)硼酸
• 中文别名: 硼酸,B-(1,3,5-三甲基-1H-吡唑-4-基)；硼酸,B-(1,3,5-三甲基-1H-吡唑-4-基)-；1,3,5-三甲基吡唑-4-硼酸；硼酸,B-(1,3,5 - 三甲基-1H-吡唑-4- 基) -
• 英文名称: (1,3,5-trimethyl-1H-pyrazol-4-yl)boronic acid
• 英文别名: 1,3,5-trimethyl-1H-pyrazol-4-ylboronic acid；1,3,5-trimethylpyrazol-4-yl boronic acid；1,3,5-trimethylpyrazole-4-boronic acid；1,3,5-pyrazole-4-boronic acid；(1,3,5-trimethylpyrazol-4-yl)boronic acid
• CAS: 847818-62-6
• 化学式: C₆H₁₁BN₂O₂
• 分子量: 153.977
• InChiKey: AWOUMBMZDWJMGM-UHFFFAOYSA-N

物化性质

• 沸点：
  326.0±52.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.28
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C，保存于惰性气体中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,3,5-Trimethylpyrazole-4-boronic acid
Synonyms: 1,3,5-Trimethyl-1H-pyrazol-4-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,3,5-Trimethylpyrazole-4-boronic acid
CAS number: 847818-62-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H11BN2O2
Molecular weight: 154.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1,3,5-三甲基-1H-吡唑-4-基)硼酸 在 四(三苯基膦)钯 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 水 、 苯甲醚 为溶剂， 反应 49.0h， 生成 9-isopropyl-3-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-14-(2-thienyl)-5,6,10,11,12,13-hexahydro[1,4]diazocino[6',7':4,5]pyrrolo[2,1-a]isoquinolin-8(9H)-one
  参考文献：
  名称：

  [EN] RING-ANNULATED DIHYDROPYRROLO[2,L-A]ISOQUINOLINES
  [FR] DIHYDROPYRROLO[2,1-A]ISOQUINOLÉINES CONDENSÉES À UN NOYAU

  摘要：

  该发明涉及按照通用式(I)或其药学上可接受的盐制备的环融合二氢吡咯并[2,1-a]异喹啉化合物。这些化合物可用于治疗不孕症。

  公开号：

  WO2011012600A1
• 作为产物：
  描述：

  3,5-二甲基-4-溴吡唑 在 氢氧化钾 、 正丁基锂 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 4.0h， 生成 (1,3,5-三甲基-1H-吡唑-4-基)硼酸
  参考文献：
  名称：

  1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成

  摘要：

  从1 H-吡唑开始，合成并表征了多种1-烷基-1 H-吡唑-4-基和1-烷基-1 H-吡唑-5-基硼酸及其频哪醇酯。所述方法中的关键步骤是吡唑环的区域选择性锂化。合成的松果酸酯在长期保存下是稳定的，可以用作有机合成中的方便试剂。

  DOI：

  10.1002/jhet.5570410612

文献信息

• Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
  作者：Xianming Deng、Barun Okram、Qiang Ding、Jianming Zhang、Yongmun Choi、Francisco J. Adrián、Amy Wojciechowski、Guobao Zhang、Jianwei Che、Badry Bursulaya、Sandra W. Cowan-Jacob、Gabriele Rummel、Taebo Sim、Nathanael S. Gray

  DOI：10.1021/jm100555f

  日期：2010.10.14

  Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competitive inhibitors of cellular Bcr-Abl kinase activity that target the myristate binding site. Here, we used cell-based structure−activity

  伊马替尼对 Bcr-Abl 激酶活性的抑制用于治疗慢性粒细胞白血病 (CML)，目前作为用小分子靶向显性癌基因的范例。我们最近报道了 GNF-2 ( 1 ) 和 GNF-5 ( 2 ) 作为靶向肉豆蔻酸结合位点的细胞 Bcr-Abl 激酶活性的选择性非 ATP 竞争性抑制剂的发现。在这里，我们使用基于细胞的结构-活性关系来指导能够与肉豆蔻酸酯结合位点结合的配体的优化和多样化，并使基于 Abl-化合物1的发现合理化共晶。我们阐明了获得针对 Bcr-Abl 转化细胞的强效抗增殖活性所需的结构-活性关系，并报告了新化合物（5g、5h、6a、14d和21j-I）的发现，这些化合物显示出改进的效力或药理特性。这项工作表明，多种结构可以有效地靶向 Bcr-Abl 肉豆蔻酸酯结合位点，并为开发可靶向该结合位点的药物提供了新的线索。
• [EN] ORAL COMPLEMENT FACTOR D INHIBITORS<br/>[FR] INHIBITEURS ORAUX DU FACTEUR D DU COMPLÉMENT
  申请人：BIOCRYST PHARM INC

  公开号：WO2021072198A1

  公开（公告）日：2021-04-15

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  揭示了式(I)的化合物及其药学上可接受的盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活性特征的疾病或状况的方法。
• Furo[3,2‐<i>b</i>]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway
  作者：Václav Němec、Michaela Hylsová、Lukáš Maier、Jana Flegel、Sonja Sievers、Slava Ziegler、Martin Schröder、Benedict‐Tilman Berger、Apirat Chaikuad、Barbora Valčíková、Stjepan Uldrijan、Stanislav Drápela、Karel Souček、Herbert Waldmann、Stefan Knapp、Kamil Paruch

  DOI：10.1002/anie.201810312

  日期：2019.1.21

  of the furo[3,2‐b]pyridine core as a novel scaffold for potent and highly selective inhibitors of cdc‐like kinases (CLKs) and efficient modulators of the Hedgehog signaling pathway. Initially, a diverse target compound set was prepared by synthetic sequences based on chemoselective metal‐mediated couplings, including assembly of the furo[3,2‐b]pyridine scaffold by copper‐mediated oxidative cyclization

  据报道，呋喃[3,2-b]吡啶核是一种新型的支架，可作为有效且高度选择性的cdc-like激酶（CLKs）抑制剂和刺猬信号通路的有效调节剂。最初，基于化学选择性金属介导的偶联，通过合成序列制备了多样化的目标化合物，包括通过铜介导的氧化环化组装呋喃[3,2-b]吡啶骨架。含有3,5-二取代的呋喃[3,2-b]吡啶的亚系列的优化提供了有效的，细胞活性的和高度选择性的CLKs抑制剂。对3,5,7-三取代的呋喃并[3,2-b]吡啶的激酶无活性子集的分析揭示了Hedgehog途径的亚微摩尔调节剂。
• Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines
  申请人：Timmers Cornelis Marius

  公开号：US20110028450A1

  公开（公告）日：2011-02-03

  The invention relates to ring-annulated dihydropyrrolo[2,1-a]isoquinoline compounds according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.

  这项发明涉及符合通用式I的环融合二氢吡咯并[2,1-a]异喹啉化合物或其药用可接受的盐。这些化合物可用于治疗不孕症。
• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION COMME MODULATEURS DES KINASES DÉPENDANTES DES CYCLINES
  申请人：NOVARTIS AG

  公开号：WO2010125402A1

  公开（公告）日：2010-11-04

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  该发明提供了式(I)的化合物及其盐、互变异构体、溶剂合物和N-氧化物；其中Q为CH或N；X为N、N+-O-或CR3；Y为N、N+-O-或CR3a；R1和R2分别选自氢和各种定义中的取代基；或R1和R2与它们连接的原子一起，形成一个可选择地取代的含氢碳环或杂环芳香或非芳香环，成员数为4到7；R3选自氢和各种取代基；R3a选自氢和各种定义中的取代基。还提供了含有式(I)的化合物的药物组合物，制备该化合物的方法以及该化合物的医药用途。式(I)的化合物具有作为CDK激酶抑制剂的活性，并可用于治疗癌症等增殖性疾病。